Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Stock Has Average Target Price of $17.75 According to Analysts

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has been given an average rating of “Moderate Buy” by the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $17.75.

AUPH has been the subject of several recent analyst reports. Weiss Ratings upgraded Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 22nd. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. Wall Street Zen downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Royal Bank Of Canada upped their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. Finally, Zacks Research downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH opened at $17.21 on Friday. Aurinia Pharmaceuticals has a twelve month low of $11.96 and a twelve month high of $19.25. The company has a market capitalization of $2.29 billion, a PE ratio of 7.52 and a beta of 1.60. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. The business’s 50-day moving average price is $16.50 and its 200 day moving average price is $15.64.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a net margin of 100.84% and a return on equity of 26.11%. The firm had revenue of $58.57 million during the quarter, compared to analysts’ expectations of $80.45 million. On average, research analysts predict that Aurinia Pharmaceuticals will post 0.91 earnings per share for the current year.

Institutional Trading of Aurinia Pharmaceuticals

Large investors have recently bought and sold shares of the business. Signaturefd LLC raised its holdings in shares of Aurinia Pharmaceuticals by 360.0% in the 3rd quarter. Signaturefd LLC now owns 1,794 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,404 shares in the last quarter. Nykredit A S acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth about $35,000. Global Retirement Partners LLC purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $41,000. Quantbot Technologies LP acquired a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth about $45,000. Finally, Frazier Financial Advisors LLC raised its holdings in Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 2,793 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.